Sep 2026
Abstract B059: Loss of Cullin-RING Ligase 5 mediates resistance to RAS inhibition in pancreatic cancer
The proto-oncogene KRAS is mutated in greater than 90% of pancreatic ductal adenocarcinoma (PDAC). Although newly developed multi-RAS(ON) inhibitors (daraxonrasib) have significantly improved progression-free and overall survival compared with current standard-of-care chemotherapy in PDAC patients, both clinical and...
Cassandra S. Markham, Ilze M. Olivi Gomes, Yi Di et al.
· Cancer Research · 0 citations